COMPANY PROFILE

Ractigen Therapeutics

Explore full profile

Pioneering RNAa therapeutics to treat undruggable diseases with innovative gene activation technology

Nantong, ChinaFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Ractigen Therapeutics

Ractigen Therapeutics is a clinical-stage pharmaceutical company specializing in the development of pioneering therapies that enhance the expression of therapeutic genes within diseased cells. Founded in 2017 by experts in RNA activation (RNAa) research, the company focuses on treating diseases that arise from inadequate gene expression. Ractigen operates primarily in the biotech and pharmaceutical markets, targeting previously undruggable diseases and monogenic disorders, including oncology, neurological and neuromuscular disorders, and liver-related conditions. The company's business model revolves around leveraging its proprietary RNAa technology to create a diverse pipeline of therapeutic solutions. Ractigen makes money through the development and commercialization of its innovative saRNA (small activating RNA) drugs, such as their groundbreaking drug RAG 01, which has advanced into the clinical stage. The company serves a range of clients, including patients, healthcare providers, and academic institutions, and collaborates with partners in both academia and industry to further its research and development efforts.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Nantong, China
Employees: 18
Open positions: 1
Dealroom signal: 68.5/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Jul 2026	$30M	$118M	China Everbright Limited · IDG Capital · Jinyu Maowu Investment · Longmen Capital	↗
SERIES AOther financing	Jan 2022	$30M	$120M	Newzone Venture Capital · Eisai · Xianghe Capital · SDIC Venture Capital	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Ractigen Therapeutics website traffic

Latest recorded traffic for Ractigen Therapeutics is 2.2K monthly website visits, up 37.5% over the last three months. Ractigen Therapeutics's team declined 10% over the past year.

Latest monthly visits2.2K 3-month web change+37.5% 1-year team growth-10%

Monthly website visitsDec 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Vice President, Business DevelopmentZhu Jiang Lu, Nantong, China · Business Development · Feb 12, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CACalmigoOffers an innovative drug free solution device providing immediate relief of anxiety and anxiety attacks	New York City, United States	Operational	24	—	—
GAGerostate AlphaGerostate Alpha is a pharmaceutical company	Novato, United States	Closed
SCSouthwest Lincoln Surgery CenterA multispecialty outpatient surgical center	Nebraska City, United States	Operational
ABArkis BioSciencesMedical device company providing minimally invasive surgical instrumentation and advanced implantable technology	Knoxville, United States	Acquired
SMSadra MedicalFocused on developing minimal invasive alternatives to surgical valve replacement and improve patient care	Campbell, United States	Acquired
AOAvitus OrthopaedicsMedical device company developing novel instruments for minimally invasive surgery	Farmington, United States	Operational
LSLattis SurgicalThe Lattis team developed a Contained Tissue Extraction (CTE) device, using bladeless technology	Cambridge, United States	Operational
RSRa Medical SystemsMedical device company that commercializes laser therapies for a number of dermatology and vascular diseases	Carlsbad, United States	Operational